<DOC>
	<DOC>NCT01904383</DOC>
	<brief_summary>Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>PMS of Trazenta on the Long-term Use as Add-on Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Inclusion criteria: Patients with type 2 diabetes mellitus who are treated with antidiabetic drugs and have never been treated with Trazenta® Tablets (linagliptin) before enrollment will be included. Exclusion criteria:</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>